NCT00352677 - Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Chronic Myeloid LeukemiaAcute Lymphocytic Leukemia

Interventions

DRUG

INNO-406

Oral, twice daily self-administration of 10 mg and/or 50 mg tablets

Trial Locations (6)

Charite University of Medicine, Berlin

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Chaim Sheba Medical Center, Tel Litwinsky

Johann Wolfgang Goethe Universität, Frankfurt am Main

University of Heidelberg Medical Clinic, Mannheim

University of Texas MD Anderson Cancer Center, Houston